Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name list(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

Synonym(s):Lisdexamfetamine dimesylate solution

  • CAS NO.:608137-33-3
  • Empirical Formula: C16H29N3O4S
  • Molecular Weight: 359.49
  • MDL number: MFCD16628114
  • EINECS: 200-659-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-08-04 20:11:12
(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE Structural

What is (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE?

Description

ADHD is a neurobehavioral disorder characterized by varying degrees of inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in childhood and affects 7–12% of the pediatric population in the United States with the condition often enduring into adulthood. While the precise mechanism of action of lisdexamfetamine in treating ADHD is not known, amphetamines are believed to inhibit the reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine), thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane.
The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.

Description

Lisdexamfetamine (mesylate) (Item No. 18050) is an analytical reference material categorized as an amphetamine. Its chemical structure consists of D-amphetamine (Item Nos. 14204 | 15650) coupled with the essential amino acid L-lysine. Lisdexamfetamine is an inactive prodrug that is converted to D-amphetamine upon cleavage of the lysine via enzymatic hydrolysis in red blood cells. Lisdexamfetamine is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

Originator

New River Pharmaceuticals (US)

The Uses of (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

Treatment of atten tion deficit hyperactivity disorder (ADHD).

brand name

Vyvanse

Synthesis

The straightforward synthesis of lisdexamfetamine mesilate was initiated by adding a solution of D-amphetamine (66) to a solution of Boc-L-Lys(Boc)-OSu (65), N-methylmorpholine and 1,4-dioxane. The resulting mixture was partitioned between isopropyl acetate and an acetic acid/brine solution, and the organic layer was washed with aqueous sodium bicarbonate to give Boc-L-Lys(Boc)- D-amphetamine (67) in 91% yield. The two primary amine groups were liberated by reacting a solution of 67 in 1,4- dioxane with methanesulfonic acid providing lisdexamfetamine mesilate (X) in 92% yield.

Synthesis_608137-33-3

Properties of (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

Flash point: 9℃
storage temp.  -20°C
form  A neat solid

Safety information for (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

Signal word Danger
Pictogram(s)
ghs
Flame
Flammables
GHS02
ghs
Skull and Crossbones
Acute Toxicity
GHS06
ghs
Health Hazard
GHS08
GHS Hazard Statements H225:Flammable liquids
H370:Specific target organ toxicity, single exposure
Precautionary Statement Codes P210:Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P260:Do not breathe dust/fume/gas/mist/vapours/spray.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P311:Call a POISON CENTER or doctor/physician.
P301+P310:IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

Computed Descriptors for (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE

You may like

  • 608137-33-3 Lisdexamfetamine dimesylate 99%
    608137-33-3 Lisdexamfetamine dimesylate 99%
    608137-33-3
    View Details
  • 608137-33-3 99%
    608137-33-3 99%
    608137-33-3
    View Details
  • Lisdexamfetamine dimesylate solution CAS 608137-33-3
    Lisdexamfetamine dimesylate solution CAS 608137-33-3
    608137-33-3
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.